Stockscreener 앱 받기
44.28
1.42%
-0.64
전일 마감가:
$44.92
열려 있는:
$45.1
하루 거래량:
1.52M
Relative Volume:
0.66
시가총액:
$7.38B
수익:
$1.56B
순이익/손실:
$152.72M
주가수익비율:
49.23
EPS:
0.8994
순현금흐름:
$221.80M
1주 성능:
+3.46%
1개월 성능:
+15.64%
6개월 성능:
+55.37%
1년 성능:
+43.86%
1일 변동 폭
$44.22
$45.71
1주일 범위
$42.19
$45.76
52주 변동 폭
$25.16
$45.76
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
44.28 | 7.38B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.13 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.57 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.96 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Why (ALKS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Christopher Wright Sells 2,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) Rule 144 notice: 2,000 vested RSU shares listed - Stock Titan
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia - MSN
Alkermes (ALKS) Receives FDA Orphan Designation for Alixorexton - GuruFocus
Alkermes (ALKS) Receives Orphan Drug Designation for Alixorexton - GuruFocus
Alkermes touts orexin ambitions as Alixorexton enters phase 3 and CEO transition nears - MSN
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Yahoo Finance
ALKS: Orexin agonist program advances with strong clinical data, strategic acquisition, and leadership transition - TradingView
ALKS: Orexin agonist advances, Avadel integration, and pipeline expansion drive strategic momentum - TradingView
Alkermes stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Australia
Alkermes PLC (ALKS) Shares Surge 4.4% -- What GF Score of 74 Tel - GuruFocus
Alkermes Jumps 5.6% After RBC Capital Maintains Outperform - AlphaStreet
Alkermes stock hits 52-week high at 44.58 USD - Investing.com
ALKS Maintained by RBC Capital -- Price Target Raised to $56.00 - GuruFocus
Alkermes' Orexin May Have Applicability Outside Sleep, RBC Says - marketscreener.com
RBC Capital raises Alkermes stock price target on pipeline potential By Investing.com - Investing.com South Africa
RBC Capital raises Alkermes stock price target on pipeline potential - Investing.com India
RBC Raises Price Target on Alkermes to $56 From $45, Keeps Outperform Rating - marketscreener.com
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
ALKS Q1 2026 Earnings: EPS Surpasses Expectations Despite Net LossEarnings Beat Alert - newsline.com
Alkermes Plc (ALKS) Stock Analysis: Strong Buy Ratings And Promising Growth Potential - DirectorsTalk Interviews
Alkermes to participate in the Goldman Sachs 47th annual global healthcare conference - MSN
Should Alkermes’ Stronger Q1 2026 Results and Sleep-Medicine Advances Prompt Action From ALKS Investors? - Yahoo Finance
Alkermes to present new data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, highlighting breadth of sleep medicine research - MSN
Alkermes Public Limited Company Trade Ideas — XETR:8AK - TradingView
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech - The Motley Fool
Insider Sell Alert: David Gaffin Sells Shares of Alkermes PLC - GuruFocus
ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes - Stocktwits
Alkermes (ALKS) Showcases Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) EVP Gaffin sells 2,034 shares under 10b5-1 plan - Stock Titan
[144] Alkermes plc. SEC Filing - Stock Titan
Alkermes plc (ALKS) Stock Price, News, Quote & History - Yahoo Finance
Alkermes to Present Sleep Medicine Research at SLEEP 2026 - GuruFocus
Alkermes (ALKS) Up 21.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Alkermes to present narcolepsy drug data at SLEEP 2026 By Investing.com - Investing.com South Africa
Alkermes to present narcolepsy drug data at SLEEP 2026 - Investing.com
New narcolepsy and hypersomnia treatment data from Alkermes at SLEEP 2026 - Stock Titan
Alkermes PLC (ALKS) Shares Surge 3.5% -- What GF Score of 75 Tel - GuruFocus
ALKS Stock Price, Quote & Chart | ALKERMES PLC (NASDAQ:ALKS) - ChartMill
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story? - simplywall.st
Understanding Momentum Shifts in (ALKS) - Stock Traders Daily
ALKS Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseEstimate Revision Count - newsline.com
Alkermes (NASDAQ: ALKS) CMO sells 9,000 shares, exercises 5,000 options under 10b5-1 plan - Stock Titan
Craig Hopkinson sells three 9,000-share tranches at Alkermes (NASDAQ: ALKS) - Stock Titan
Alkermes plc (ALKS) Stock Analysis: Solid Growth Potential with 28.2% Revenue Surge and Analyst Consensus - DirectorsTalk Interviews
Alkermes Insider Sold Shares Worth $687,007, According to a Recent SEC Filing - marketscreener.com
Tranche Update on Alkermes plc's Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.37%
0.50%
자본화:
|
볼륨(24시간):